Entering text into the input field will update the search result below

Human Microbiome Market – Global Industry Segmentation, Emerging Trends & Future Forecasts

Jan. 04, 2021 12:23 AM ETSeres Therapeutics, Inc. (MCRB), DD, SYBXFRPRQ
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Seeking Alpha Analyst Since 2014

#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology

Summary

  • Investigational New Drug Requirements for Fecal Microbiota.
  • Increasing Collaborations.

Research Methodology Followed for Study of Global Human Microbiome Market:

Primary Research:

Primary sources were several industry experts from core-related industries and preferred suppliers, manufacturers, distributors, service providers, reimbursement providers, technology developers, and doctors. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. Primary sources from the demand side include key opinion leaders in hospitals.

Secondary Research:

In the secondary research process, various sources such as directories, and databases (such as Bloomberg Business and Factiva) to identify and collect information useful for this technical, market-oriented, and commercial study of the global human microbiome market. These secondary sources include World Health Organization (WHO), Human Microbiome Project (HMP), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), Food and Drug Administration (FDA), ClinicalTrials.gov, Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis.

Expected Revenue Surge:

The global human microbiome market is projected to reach USD 1,731 million in 2027 from USD 942 million in 2024, at CAGR of 22.5 % during the forecast period.

Industry Segmentation:

Human Microbiome Market is segmented by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic/Endocrine, Cancer, Blood, Neurological), Research Technology (Proteomics, Metabolomics) and geography.

Download PDF Brochure@ Human Microbiome Market

Major Growth Boosters:

Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and detailed research on the human microbiome is restraining the growth of this market.

Regional Growth:

The market in North America is expected to grow at the highest CAGR during the forecast period.

The market in North America is estimated to grow at the highest CAGR during the forecast period. Factors such as the increasing incidence of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotic products are the factors driving the North American market.

Key questions addressed by the report:

# Who are the major market players in the human microbiome market?

# What are the regional growth trends and the largest revenue-generating regions for the market?

# What are the major drivers and challenges in the market?

# What are the major product segments in the market?

# What are the major technologies used in the human microbiome research spending market?

Request Sample Pages@ Human Microbiome Market

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.